• Japanese
  • Korean
  • Chinese
Cover Image

Growth Factors (Blood And Tissue)

Abstract

This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in US$ Million by the following growth factor types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 90 companies including many key and niche players such as Alseres Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance GeneMedix Plc, Johnson & Johnson, Janssen, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc. (GIA) is a reputed publisher of off-the-shelf market research. Recognized as one of the most consistently accurate forecasting company in the world, GIA currently serves more than 9,500 companies from 36 countries worldwide. The company was founded in 1987, initially recognized globally as a research boutique specializing in the medical industry. Over the past 25 years, the company expanded its coverage and now publishes extensively upon more than 180 major industries.

Our experienced team is dedicated to world-class research and analysis. We attribute our success to our people, their commitment and work culture.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Blood Growth Factors
      • Erythropoietins
      • Colony Stimulating Factors
      • Interferons
      • Interleukins
    • Tissue Growth Factors

II. EXECUTIVE SUMMARY

1. INTRODUCTION

  • Growth Factors: A Preface
  • Growth Factors: Their Role and Related Applications
  • Growth Factors: Adding a New Dimension
  • Growth Factors: Classification Based on Activity
  • Recent Trends & Developments
  • Recombinant Human Erythropoietin: Gradually Gaining Dominance
    • Leading EPO Drugs Worldwide
    • Market Comparison of Erythropoietin-Based Drugs in America and European Union
    • Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007
  • Patent Expiries of Biopharmaceuticals in Developed Regions - Europe and United States

2. MARKET DYNAMICS

  • Major Companies Impacted by Patent Expiries
  • Patent Expiries Fuel Competition and Sales
  • Side Effects - Still a Concern
  • CDER- A Regulatory Review Authority for Growth Factors
  • Innovative Delivery System Shows Potential for Accelerating Use of Growth Factors
  • Cytokines- Vital Growth Propellers for the Future of New Drugs
  • Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application
  • Age-Related Diseases - Their Influence on Effective Therapies
  • Mimetic Growth Factors - Exhibiting Promising Potential
  • India - At the Center Stage...

3. INDUSTRY ISSUES

  • Development of Cost Effective Methods - Need of the Hour
  • Influence of Neurotrophic Factors on Brain Cell Development
  • Combination of Interferons and Ribavirin Develops More Anemia Cases

4. GROWTH FACTORS - AN OVERVIEW

  • Blood Growth Factors
  • Erythropoietins
    • Types of Erythropoietins
      • Epoetin
      • Darbepoetin
      • Aranesp(r)
      • Aranesp Vs. Other EPOs
    • Recombinant Human EPO (rHuEPO)
  • Colony Stimulating Factors
    • Granulocyte-Colony Stimulating Factor
    • Granulocyte Macrophage-Colony Stimulating Factor
    • Other Colony Stimulating Factors
      • Macrophage Colony Stimulating Factor (M-CSF)
      • Key Functions of M-CSF
    • Side-Effects of Colony-Stimulating Factors
  • Interferons
    • Types of Interferons
    • Interferon-gamma
    • 1a and 1b: Two Key Biochemical Forms of Interferon-β
    • PEG-Intron
      • Types of Interferons
  • Interleukins
    • Types of Interleukins
  • Tissue Growth Factors
  • Wound Healing Growth Factors
  • Neurotrophic Growth Factors
    • Nerve Growth Factor
  • Vascular Endothelial Growth Factor (VEGF)
  • Fibroblast Growth Factor (FGF)
  • Insulin-Like Growth Factor-I (IGF-I)
  • Insulin-Like Growth Factor-II (IGF-II)
    • Tissue Growth Factors: Classification Based on Key Source and Principal Activity
  • Platelet - Derived Growth Factors in Wound Healing
    • Thrombopoietin (TPO)
  • Growth Factors: Their Mode of Action in Tissue Repair
  • Angiogenesis: Their Role in Wound Healing
  • Angiogenesis As an Alternative for Cardiac Stents
  • Applications of Growth Factors
  • Growth Factors: Site/Course of Action and Applications

5. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST REVIEW

  • Maxygen Updates on Factor VII Program
  • Evaluation of Extended Dosing Schedule of PROCRIT(r)
  • PROCRIT(r) - A Better Option
  • Nerve Growth Factor Shows Promising Potential Against Diabetes
  • Cytokines and GM-CSF Found to be Closely Interlinked
  • GM-CSF Enhances Rate of Survival in Neonates
  • rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients
  • rG-CSF- Their Influence on Preterm Infants with Sepsis
  • Serum Macrophage Colony Stimulating Growth Factors Associated with Thrombocyte and Monocyte
  • Src Pathway Inactivation in Kit Impairs Blood Cell Growth and Proliferation
  • Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth of Blood Vessels
  • Effect of Brain Derived Neurotrophic Factor on Retinal Cells
  • Orcel(tm) Exhibits High Growth Factor for Wound Healing and Cardiovascular Applications
  • Drug Combination of Macrophage Colony Stimulating Factor Shows Successful Tolerance Levels
  • Neotrofin(tm) Triggers Neurotrophic Factors
  • G-CSF Shows Capability for Promoting Neutrophil Production
  • Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing Process
  • Hepatocyte Growth Factors - Exhibiting Dual Role
  • Cortex Pharmaceuticals Ampakines(r) Promotes Expression of Neurotrophin
  • Granulocyte Colony Stimulating Factor Finds Application in Treating Neonates
  • Cerebrolysin Promotes Cognition

6. BREAKTHROUGHS - A RECENT PAST REVIEW

  • Novel Set of Human Cytokines Unveiled
  • IGFBP-3 and its Potential to Ward Off Gastric Cancer
  • Bone Morphogenic Proteins Show Potential for Musculoskeletal Regeneration
  • Growth Factors - Their Role in Preventing Heart Stroke
  • Growth Factor Proteins Show Promising Results for Treating Cancer
  • Neurotrophic Growth Factor - Primarily Responsible for Loss of Vision
  • Redox-Active Grape Seed Exhibits Favorable Properties for Dermal Wound Healing
  • Role of Brain-Derived Neurotrophic Factor on Memory
  • Nerve Growth Factor Found to Enhance Barium Current and Insulin Secretion
  • Lipid Peroxidation May be Associated with Wound Healing
  • Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels
  • Connective Tissue Growth Factor Found to Promote Lung Fibroblast
  • Influence of Insulin-Like Growth Factor on Growth
  • Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and Repair
  • Environment and Insulin-Like Growth Factors Stimulate Risk of Cancer
  • Cocktail of Neurotrophic Factors Promotes Regeneration of Torn Nerves
  • Growth Factors Administration to Stimulate Tissue Repair
  • Cytokine - Their Role in Combating Hepatitis C Virus
  • Axokine(r) Yields Favorable Results Against Obesity
  • Cell Genesys Unveils GDNF Gene Therapy Targeted Against Parkinson's Disease

7. PRODUCT INTRODUCTIONS/INNOVATIONS

  • Sandoz Unveils Zarzio
  • Wockhardt Launches Three Biotechnology Products
  • Extavia(r) Receives Approval from European Commission
  • Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric Patients
  • Hospira Receives EC Approval on Retacrit
  • Tercica Receives FDA Approval For Increlex
  • Ventria Bioscience Introduces Lacromin
  • Dragon Pharmaceuticals Bags Market Approval from Chinese SDA
  • DPI Receives Approvals for Erythropoietin in Three New Markets
  • Wockhardt Introduces Wepox Recombinant Erythropoietin Drug
  • Shanta Biotechnics Unveils Shanferon
  • SkinMedica Unveils TNS Recovery Complex(tm) Gel
  • CellGenix Unveils Cytokines for Cell Applications
  • Cel-Sci Corporation Develops Multikine
  • Wockhardt Limited Unveils EPOX(tm)

8. RECENT INDUSTRY ACTIVITY

  • Soluble Systems Collaborates with LifeNet Health's Subsidiary to Introduce TheraSkin(tm)
  • GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership
  • Sanofi Takes Over Shantha Biotech
  • Kaken Pharmaceutical Enters into Licensing Agreement with Olympus Corporation

9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER

  • Biovitrum and Amgen Sign Agreement
  • Merck Establishes Production Unit
  • Eli Lilly and Company Acquires ImClone Systems
  • GeneMedix Changes Name to Reliance GeneMedix
  • FDA Approves Label Expansion for VIDAZA
  • Pfizer Inks Exclusive Global Licensing Agreement with Scil Technology
  • ZGEN Initiates Ph II Trial of Interleukin 21
  • FzioMed Bags Health Canada Approval on Oxiplex(r)
  • NsGene A/S Implants Encapsulated Cell in Patients
  • Reliance Life Sciences Takes Over Genemedix
  • Fraunhofer Institute Introduces First Interferon Beta 1a to Treat Multiple Sclerosis
  • Shanghai Wanxing Inks Export Deal for Recombinant Human Interferon
  • Hemispherx Enters into Distribution Agreement with Armada
  • Bayer Establishes US Pharmaceuticals Subsidiary
  • Merck Inks Agreement with Bristol-Myers Squibb and ImClone
  • CoGenesys Signs Global Licensing Agreement with Vegenics
  • InterMune Inks New Supply Deal with Boehringer Ingelheim
  • Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals
  • Cambrex Divests Bioproducts and Biopharma Subsidiaries
  • Dragon Divests EPO Business
  • Caregene and Genzyme Forms Partnership to Develop Cere-120
  • NsGene to Undertake Phase Ib Clinical Trial of NsG0202
  • Roche Receives European approval for NeoRecormon
  • Bolder Receives Two U.S. Patents for Hematopoietic Factors
  • RLS to Initiate Clinical Trials of Erythropoietin
  • InterMune Drops Phase III trial of Interferon
  • Chugai to Conduct Additional Trial on Epogin(r)
  • Merck KGaA Acquires Serono Labs
  • CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences
  • Hospira Signs Agreements with STADA and BIOCEUTICALS for Erythropoietin
  • Biocon Bags GEAC Approval to Conduct Clinical Trial of Granulocyte Colony Stimulating Factor
  • SII to Conduct Clinical Trials of Rdna Products
  • Claris to Construct Production Facility for EOP
  • Mayne and Pliva to End Collaboration on Erythropoietin Development
  • GeneMedix Collaborates with CJ Corp.
  • FzioMed and USC Enter into Licensing Agreement for Oligopeptides
  • AnGes MG Enters Into An Agreement with Vical
  • Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA
  • Dragon Pharmaceuticals Acquires Oriental Wave
  • Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series
  • Amrad and Ludwig Institute Jointly Focus on the Development of VEGF-B
  • GeneMedix Restructures Business
  • pSivida Limited Collaborates with Ian Wark Research Institute
  • Amgen Acquires Tularik
  • BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S(tm)
  • Chugai and Roche Expand Drug Research Synergies
  • Dragon Pharmaceuticals to Construct New Production Facility
  • FibroGen Signs Contract with Yamanouchi for Licensing EPO Small Molecule
  • Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine
  • Maxygen and Rentschler Enter into a Contract for G-CSF
  • Maxygen Signs Agreement with Biovitrum for Manufacturing Beta Interferon
  • Dragon Pharmaceuticals Signs Agreement with Zhongkai
  • Dragon Pharmaceuticals Enters into Definitive Agreement with Oriental Wave
  • Zymogenetics Bags US FDA Clearance
  • Ceregene Bags Patent

10. FOCUS ON SELECT GLOBAL PLAYERS

  • Alseres Pharmaceuticals, Inc. (USA)
  • Amgen, Inc. (USA)
  • Bayer HealthCare Pharmaceuticals, Inc. (USA)
  • BioMimetic Therapeutics, Inc. (USA)
  • Biopharm GmbH (Germany)
  • Bolder Biotechnology, Inc. (USA)
  • Ceregene, Inc. (USA)
  • FibroGen, Inc. (USA)
  • FzioMed, Inc. (USA)
  • Genzyme Corporation (USA)
  • Novo Nordisk A/S (Denmark)
  • Reliance GeneMedix Plc. (UK)
  • Johnson & Johnson (USA)
  • Janssen, Inc. (Canada)
  • Lonza Group (Switzerland)
  • Maxygen, Inc. (USA)
  • Merck Serono International S.A. (Switzerland)
  • NsGene A/S (Denmark)
  • PeproTech, Inc. (USA)
  • Rentschler Biotechnologie GmbH (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Chugai Pharmaceutical Co. Ltd. (Japan)
  • Genentech, Inc. (USA)
  • Shantha Biotechnics (India)
  • Scil Proteins GmbH (Germany)
  • Wockhardt Ltd. (India)

11. GLOBAL MARKET PERSPECTIVE

    • Table 1: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 2: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 3: World 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 4: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 5: World Historic Review for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 003 through 2008 (includes corresponding Graph/Chart)
    • Table 6: World 15-Year Perspective for Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
    • Table 7: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 8: World Historic Review for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 9: World 15-Year Perspective for Blood Growth Factors by Type - Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 10: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 12: World 15-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
    • Table 13: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 15: World 15-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 18: World 15-Year Perspective for Interferons as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 21: World 15-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 22: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 23: World Historic Review for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 24: World 15-Year Perspective for Tissue Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Leading EPO Drugs in the US
  • B. Market Analytics
    • Table 25: The US Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 26: The US Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 27: The US 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2. JAPAN

  • A. Market Analysis
    • Erythropoietin Market
      • Leading EPO Drugs in Japan
    • Market Scenario for Biotech Products
      • Biotech Market Backed by Public Assistance
  • B. Market Analytics
    • Table 28: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 29: Japanese Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 30: Japanese 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Erythropoietin Market
      • Leading EPO Drugs in Europe
  • B. Market Analytics
    • Table 31: European Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 32: European Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 33: European 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • An Overview of Indian Market
      • Erythropoietin
      • G-CSF Market
      • Interferon
  • B. Market Analytics
    • Table 34: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 35: Rest of World Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 36: Rest of World 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Show More
Pricing
Get Notified
Email me when related reports are published